Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-30
2011-08-30
Dahle, Chun (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100
Reexamination Certificate
active
08008443
ABSTRACT:
The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
REFERENCES:
patent: 5624821 (1997-04-01), Winter et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5885573 (1999-03-01), Bluestone et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward et al.
patent: 6737056 (2004-05-01), Presta et al.
patent: 7276585 (2007-10-01), Lazar et al.
patent: 7659374 (2010-02-01), Wu et al.
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0147311 (2002-10-01), Gillies et al.
patent: 2003/0157108 (2003-08-01), Presta
patent: 2003/0190311 (2003-10-01), Dall'Acqua et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0121415 (2004-06-01), King et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2005/0032114 (2005-02-01), Hinton et al.
patent: 2005/0037000 (2005-02-01), Stavenhagen
patent: 2005/0054832 (2005-03-01), Lazar et al.
patent: 2005/0064514 (2005-03-01), Stavenhagen
patent: 2005/0215768 (2005-09-01), Armour et al.
patent: 2005/0244403 (2005-11-01), Lazar et al.
patent: 2006/0275283 (2006-12-01), van Vlijmen et al.
patent: 2007/0148164 (2007-06-01), Farrington et al.
patent: 2007/0275460 (2007-11-01), Desjarlais et al.
patent: 2009/0053240 (2009-02-01), Lazar et al.
patent: WO-91-01335 (1991-02-01), None
patent: WO-94-29351 (1994-12-01), None
patent: WO-98-05787 (1998-02-01), None
patent: WO-98-23289 (1998-06-01), None
patent: WO-99-15549 (1999-04-01), None
patent: WO-99-58572 (1999-11-01), None
patent: WO-03-074679 (2003-09-01), None
patent: WO-2004-099249 (2004-11-01), None
patent: WO-2005-000899 (2005-01-01), None
patent: WO 2005-047327 (2005-05-01), None
patent: WO-2005-070963 (2005-08-01), None
patent: WO-2005-092925 (2005-10-01), None
patent: WO-2006-076594 (2006-07-01), None
patent: WO-2006-116260 (2006-11-01), None
Alegre, M. L., et al. “A Non-Activating “Humanized” Anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties in Vivo.”Transplantation(1994) 57: 1537-43.
Armour, K. L., et al. “Recombinant Human IgG Molecules Lacking Fcgamma Receptor I Binding and Monocyte Triggering Activities.”Eur.J.Immunol.(1999) 29: 2613-24.
Bastida-Corcuera et al., “Differential complement activation by bovine IgG2 allotypes.”Vet Immunol Immunopathol(1999) 71:115-123.
Brekke et al., “Activation of complement by an IgG molecule without a genetic hinge.”Nature(1993) 363:628-30.
Brekke et al., “The structural requirements for complement activation by IgG: does it hinge on the hinge?”Immunol. Today(1995) 16:85-90.
Bruggemann, M., et al. “Comparison of the Effector Functions of Human Immunoglobulins using a Matched Set of Chimeric Antibodies.”J.Exp.Med.(1987) 166: 1351-61.
Clynes, R., et al. “Fc Receptors are Required in Passive and Active Immunity to Melanoma.”Proc.Natl.Acad.Sci.U.S.A.(1998) 95: 652-6.
Coloma et al., “The Hinge as a Is Required for Spacer Contributes Function of IgG”J. Immunol.(1997)158:733-40.
Dall'Acqua, W. F., et al. “Modulation of the Effector Functions of a Human IgG1 through Engineering of its Hinge Region.”J.Immunol.(2006) 177: 1129-38.
Dangl et al., “Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.”EMBO(1988) 71989-94.
Duncan, A. R., et al. “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG.”Nature(1988) 332: 563-4.
Ghetie, V., et al. “Increasing the Serum Persistence of an IgG Fragment by Random Mutagenesis.”Nat.Biotechnol.(1997) 15: 637-40.
Gillies and Wesolowsi, “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor speciicities.”Hum. Antibod. Hybridomas(1990) 1: 47-54.
Hutchins, J. T., et al. “Improved Biodistribution, Tumor Targeting, and Reduced Immunogenicity in Mice with a Gamma 4 Variant of Campath-1H.”Proc.Natl.Acad.Sci.U.S.A.(1995) 92: 11980-4.
Idusogie, E. E., et al. “Engineered Antibodies with Increased Activity to Recruit Complement.”J.Immunol.(2001) 166: 2571-5.
Idusogie, E. E., et al. “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc.”J.Immunol.(2000) 164: 4178-84.
Jefferis, R., et al. “Interaction Sites on Human IgG-Fc for FcgammaR: Current Models.”Immunol.Lett.(2002) 82: 57-65.
Jefferis, R., et al. “Modulation of Fc(Gamma)R and Human Complement Activation by IgG3-Core Oligosaccharide Interactions.”Immunol.Lett.(1996) 54: 101-4.
Jefferis, R., et al. “Recognition Sites on Human IgG for Fc Gamma Receptors: The Role of Glycosylation.”Immunol.Lett.(1995) 44: 111-7.
Klein et al., “Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.”Proc Natl Acad Sci USA(1981) 78: 524-8.
Lund, J., et al. “Multiple Interactions of IgG with its Core Oligosaccharide can Modulate Recognition by Complement and Human Fc Gamma Receptor I and Influence the Synthesis of its Oligosaccharide Chains.”J.Immunol.(1996) 157: 4963-9.
Lund, J., et al. “Oligosaccharide-Protein Interactions in IgG can Modulate Recognition by Fc Gamma Receptors.”FASEB J.(1995) 9: 115-9.
Lund, J., et al. “Multiple Binding Sites on the CH2 Domain of IgG for Mouse Fc Gamma R11.”Mol.Immunol.(1992) 29: 53-9.
Lund, J., et al. “Human Fc Gamma RI and Fc Gamma RII Interact with Distinct but Overlapping Sites on Human IgG.”J.Immunol.(1991) 147: 2657-62.
MedImmune Inc. “International Preliminary Report on Patentability and Written Opinion of the International Searching Authority for PCT/US2006/015393.” : 1-5.
MedImmune, Inc. “Supplementary European Search Report for EP 06 75 1192” 1-11.
Oi, T., et al. “Correlation between segmental flexibility and effector function of antibodies.”Nature(1984) 307: 136-40.
Patel, A. K., et al. “An Improved Assay for Antibody Dependent Cellular Cytotoxicity Based on Time Resolved Fluorometry.”J.Immunol.Methods(1995) 184: 29-38.
Presta, L. G., et al. “Engineering Therapeutic Antibodies for Improved Function.”Biochem.Soc.Trans.(2002) 30: 487-90.
Radaev, S., et al. “Recognition of immunoglobulins by Fcγ receptors.” Mol. Immunol. (2001) 38:1073-83.
Reddy, M. P., et al. “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4.”J.Immunol.(2000) 164: 1925-33.
Redpath, S., et al. “Activation of complement by human IgG1 and IgG3 antibodies against the human leucocyte antigen CD52.” Immunology (1998) 93:595-600.
Redpath, S., et al. “The Influence of the Hinge Region Length in Binding of Human IgG to Human Fcγ Receptors.” Human Immunol. (1998) 59:720-27.
Shields, R. L., et al. “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity.”J.Biol.Chem.(2002) 277: 26733-40.
Shields, R. L., et al. “High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc Gamma R.
Casa-Finet Jose
Dall'Acqua William
Damschroder Melissa
Wu Herren
Dahle Chun
MedImmune LLC
LandOfFree
Modulation of antibody effector function by hinge domain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of antibody effector function by hinge domain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of antibody effector function by hinge domain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2732727